About VISEN Pharmaceuticals
VISEN Pharmaceuticals is a publicly listed company based in Shanghai (China) founded in 2018. It operates as a therapeutics for endocrine diseases are developed using TransCon technology. VISEN Pharmaceuticals has raised $150 million across 1 funding round from investors including Ascendis Pharma, Orbimed and HBM Healthcare Investments. The company has 3 employees. Its chief executive is Pony Lu. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Endocrine disorders. Its legal entity is VISEN. Its competitors include Neurocrine, Ironwood Pharma, Crinetics, Zucara Therapeutics and MBX Biosciences and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
VISEN Pharmaceuticals was founded in 2018 and is headquartered in Shanghai, China. Operations focus on the biotechnology sector, where therapeutics for endocrine-related diseases are developed through the proprietary TransCon platform for transient conjugation. Key products include TransCon hGH for pediatric growth hormone deficiency, TransCon PTH for hypoparathyroidism, and TransCon CNP for achondroplasia, addressing deficiencies in hormone secretion or gland function.
- Headquarters Shanghai, China
- Employees 3
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website visenpharma.com/cn
- Social LinkedIn
- Legal Name Visen Pharmaceuticals
- Annual Revenue$22.99 K (USD)0as on Dec 31, 2025
- Net Profit-$35.31 M (USD)-39.1as on Dec 31, 2025
- EBITDA-$32.97 M (USD)-37.22as on Dec 31, 2025
- Total Equity Funding$150M (USD)
in 1 rounds
- Latest Funding Round$150M (USD), Series B
Jan 2021
- InvestorsAscendis Pharma
& 9 more
- Employee Count3
Funding Insights of VISEN Pharmaceuticals
VISEN Pharmaceuticals has successfully raised a total of $150M through 1 strategic funding round. The most recent funding activity was a Series B round of $150 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $150M
- Total Rounds 1
- Last Round Series B — $150M
- First Round $150M
(Jan 2021)
- Investors Count 10
All 1 funding rounds of VISEN Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $150M | Series B | – | Sequoia Capital |
10 investors in total: 10 institutional.
Investors in VISEN Pharmaceuticals
VISEN Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Ascendis Pharma, Orbimed and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | sherpavc.com.cn | - | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
A venture capital firm focused on life sciences innovation. | 2017 | pivotalbiovp.cn | Hong Kong, Hong Kong SAR | |
Biotech funding, drug development support, and investment in life sciences. | – | sofinnova.com | - | |
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | - | |
Venture capital and private equity firm | – | vivocapital.com | Palo Alto, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
CDG Capital is engaged in providing financial and investment services. | – | cdgcapital.ma | Rabat, Morocco | |
Long-acting prodrug therapies are developed for endocrine and rare diseases. | 2007 | ascendispharma.com | Hellerup, Denmark | |
- | – | logoscapital.io | - |
Investor details for VISEN Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of VISEN Pharmaceuticals
4 people are tracked at VISEN Pharmaceuticals (3 in leadership, 1 in team); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Pony Lu | CEO | Leadership |
Jing Zhu | Senior Director, Head Of CMC | Leadership |
Gavin Yi Guo | Vice President Of Business Development | Leadership |
Xiaoxu Zhang | Human Resources Senior Manager | Team |
Complete people profiles for VISEN Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of VISEN Pharmaceuticals
VISEN Pharmaceuticals is a publicly listed company on the HKEX with ticker symbol 2561 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Mar 2025
- Listed onHKEX: 2561
- Listed entityVISEN Pharmaceuticals
- Exchange sectorHealth technology
- ISINKYG93Y5D1039
- Share price18.50 HKD (-0.05% on the day) · 2026-10-14
- Market capitalisation2,108,786,290.00 HKD
- EPS (diluted, trailing year)-2.45 HKD
- Volume (last session)4,700
Financials of VISEN Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 178,950 HKD | -274.8M HKD | -256.6M HKD |
| 2024 | – | -197.6M HKD | -187.0M HKD |
| 2023 | – | -275.8M HKD | -144.3M HKD |
| 2022 | – | -336.0M HKD | -406.5M HKD |
| 2021 | – | -584.3M HKD | -533.9M HKD |
Detailed financial statements for VISEN Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of VISEN Pharmaceuticals
3 dated milestones of VISEN Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.
- Founded VISEN Pharmaceuticals is founded.
- Funding First funding round of $150.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of VISEN Pharmaceuticals
VISEN Pharmaceuticals has 9 listed competitors in our database, 9 of them funded. They include Neurocrine, Ironwood Pharma, Crinetics, Zucara Therapeutics and MBX Biosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| crinetics.com | 2008 | San Diego, United States | $103.5M | 120 | Developer of therapies for the treatment of endocrine-related diseases and cancers | |
| zucara.ca | 2015 | Vancouver, Canada | $50.82M | 12 | Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes | |
| mbxbio.com | 2018 | Carmel, United States | $215.6M | 11 | Drugs for rare endocrine diseases are developed and advanced. | |
| radionetics.com | 2021 | San Diego, United States | $136.71M | – | Peptide-targeted radiopharmaceuticals for cancer treatment are developed. | |
| sioltatherapeutics.com | 2016 | San Francisco, United States | $42M | – | Microbiome therapeutics are provided for treating chronic inflammatory diseases. | |
| veradermics.com | 2020 | San Antonio, United States | $262.71M | – | Drug-delivery platforms for pediatric wart treatments are developed. | |
| diasome.com | 2005 | Cleveland, United States | $72.63M | – | Developer of therapies for the treatment of diabetes and other metabolic conditions |
Detailed competitors of VISEN Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
10 companies that operate in the same segment as VISEN Pharmaceuticals (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | 71 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Visen Pharmaceuticals
Complete news archive for VISEN Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VISEN Pharmaceuticals
VISEN Pharmaceuticals was founded in 2018 and raised its 1st funding round 3 years after it was founded.
VISEN Pharmaceuticals is headquartered in Shanghai, China.
Pony Lu is the current CEO of VISEN Pharmaceuticals.
VISEN Pharmaceuticals is a funded company, having raised a total of $150M across 1 funding round to date. The company's 1st funding round was a Series B of $150M, raised on Jan 2021.
VISEN Pharmaceuticals has 3 employees.
Annual revenue of VISEN Pharmaceuticals is $22.99K as on Dec 31, 2025.
VISEN Pharmaceuticals was founded in 2018 and is headquartered in Shanghai, China. Operations focus on the biotechnology sector, where therapeutics for endocrine-related diseases are developed through the proprietary TransCon platform for transient conjugation. Key products include TransCon hGH for pediatric growth hormone deficiency, TransCon PTH for hypoparathyroidism, and TransCon CNP for achondroplasia, addressing deficiencies in hormone secretion or gland function.
VISEN Pharmaceuticals's top competitors include Ironwood Pharma, Crinetics and Neurocrine.
Yes, VISEN Pharmaceuticals is publicly traded on HKEX under the ticker symbol 2561.
VISEN Pharmaceuticals has 10 investors. Key investors include Ascendis Pharma, Orbimed, HBM Healthcare Investments, Sherpa Venture Capital, and Pivotal bioVenture Partners.
VISEN Pharmaceuticals operates through Visen.